South Korea’s Quarantine and Inspection Agency (검역본부) has convened a high-level academic workshop to accelerate domestic research into advanced veterinary vaccines, with a focus on virus vector and fusion protein platforms to combat foot-and-mouth disease (FMD), African swine fever (ASF), and avian influenza. The event, attended by leading virologists and government officials, marks a pivotal step in strengthening the country’s biosecurity infrastructure amid rising global threats to livestock and poultry industries.
The workshop, held in Seoul earlier this month, brought together researchers from the Korea Disease Control and Prevention Agency (KDCA), the Animal and Plant Quarantine Agency (APQA), and top universities including Seoul National University and Gyeongsang National University. Participants emphasized the urgent need for domestically developed vaccines to reduce reliance on imports and enhance preparedness for potential outbreaks.
According to a statement from the APQA, the workshop highlighted three key technological platforms: virus vector-based vaccines, which use modified viruses to deliver protective antigens; fusion protein vaccines, designed to trigger stronger immune responses; and next-generation mRNA technologies adapted for veterinary use. “The integration of these platforms will allow us to develop vaccines that are not only highly effective but also adaptable to emerging variants,” said Dr. Lee Jung-ho, director of the APQA’s Veterinary Research Division.
Why South Korea Is Investing in Domestic Vaccine Development
South Korea’s push for self-sufficiency in veterinary vaccines stems from recent disruptions in global supply chains and the economic toll of animal disease outbreaks. In 2023 alone, ASF outbreaks in neighboring China and Southeast Asia cost South Korean farmers an estimated $1.2 billion in lost revenue and culling expenses, according to the Ministry of Agriculture, Food and Rural Affairs (MAFRA). The workshop underscored that while the country has made progress—such as developing a commercial vaccine for avian influenza in 2022—critical gaps remain for FMD and ASF, which have no approved domestic solutions.
Dr. Park Soo-jin, a professor of veterinary medicine at Seoul National University and a workshop speaker, noted that the new platforms could slash vaccine development timelines from years to months. “Traditional inactivated vaccines require extensive testing and often fail to provide broad protection against new strains,” she said. “By leveraging recombinant DNA techniques, we can design vaccines that target multiple antigens simultaneously.”
Key Diseases Targeted by the New Research
- Foot-and-Mouth Disease (FMD): A highly contagious viral disease affecting cloven-hoofed animals, including cattle and pigs. The last major outbreak in South Korea occurred in 2010, but the country remains vigilant due to its proximity to endemic regions in Asia. The World Organisation for Animal Health (OIE) classifies FMD as one of the most economically devastating livestock diseases globally.
- African Swine Fever (ASF): A viral hemorrhagic fever with near-100% mortality in wild boars and domestic pigs. Since 2018, ASF has spread across Asia, Europe, and Africa, forcing South Korea to implement strict biosecurity measures, including mass culling and border restrictions. The FAO estimates that ASF has killed over 6 million pigs worldwide since 2018.
- Avian Influenza (Bird Flu): While South Korea has successfully deployed vaccines for H5N1 and H5N8 strains, experts warn that new variants—such as the highly pathogenic H5N6 detected in 2023—pose ongoing risks. The country’s poultry industry, valued at $3.5 billion annually, is particularly vulnerable.
How South Korea’s Approach Compares to Global Efforts
The APQA’s workshop aligns with global trends in veterinary vaccine innovation, but South Korea’s strategy stands out for its focus on domestic capacity-building. Unlike the U.S. or EU, which rely on established pharmaceutical giants like Merck Animal Health or Zoetis, South Korea is prioritizing public-private partnerships to reduce dependency on foreign suppliers. “We’re not just importing technology; we’re adapting it to our agricultural ecosystem,” said Dr. Choi Min-kyu, a senior researcher at the Korea Research Institute of Bioscience and Biotechnology (KRIBB), which is collaborating on the project.
A comparison with China—another major player in veterinary vaccine development—reveals both similarities and differences. China has rapidly scaled up production of ASF vaccines, with companies like Sinovac and China Animal Husbandry Industry Co. supplying vaccines to Southeast Asia. However, South Korea’s approach is more collaborative, with the government funding university-led research hubs rather than relying solely on state-owned enterprises.
In contrast, the EU’s veterinary vaccine market is dominated by multinational corporations, with Zoetis and Merck Animal Health controlling over 60% of the market. South Korea’s model reflects a deliberate shift toward sovereignty in critical infrastructure, echoing its broader strategy in semiconductor manufacturing and pharmaceuticals.
What Happens Next: Timeline and Stakeholder Actions
The APQA has outlined a three-phase roadmap for the next 18 months:
- Phase 1 (Immediate): Finalize prototype vaccines for FMD and ASF using the platforms discussed in the workshop. Target completion: June 2025.
- Phase 2 (Mid-Term): Conduct field trials in controlled environments (e.g., quarantine farms) and seek emergency approvals for high-risk regions. Target completion: December 2025.
- Phase 3 (Long-Term): Scale production and establish a national vaccine stockpile, with the goal of achieving 70% domestic self-sufficiency by 2030.
Stakeholders involved include:
- The Korea Disease Control and Prevention Agency, which will oversee clinical trials.
- Private sector partners such as Cheil Jedang, a major food and pharmaceutical company, which has pledged $50 million in funding for vaccine development.
- The South Korean government, which has allocated an additional $80 million in the 2024 budget for veterinary biosecurity research.
Why This Matters: Global Biosecurity and Economic Resilience
The workshop’s outcomes carry significant implications for both South Korea and the global animal health community. Economically, the development of domestic vaccines could reduce the country’s reliance on imports, which currently account for over 40% of its veterinary pharmaceutical needs. Politically, it strengthens South Korea’s position in regional biosecurity alliances, such as the ASEAN and the OIE, where it has increasingly taken a leadership role in disease surveillance.
Public health experts also highlight the indirect benefits. “Animal diseases don’t stay in the barn,” said Dr. Kim Hyeon-ju, an infectious disease specialist at Yonsei University. “By strengthening our veterinary vaccine infrastructure, we’re also building a first line of defense against zoonotic spillover—diseases that can jump from animals to humans.” The WHO estimates that 60% of emerging infectious diseases in humans originate in animals, making robust veterinary systems a global priority.
Where to Find Official Updates and Safety Guidance
For the latest developments on South Korea’s veterinary vaccine research, readers can monitor the following official sources:
- Animal and Plant Quarantine Agency (APQA) – Official statements and research updates.
- Korea Disease Control and Prevention Agency (KDCA) – Disease surveillance and outbreak alerts.
- Ministry of Agriculture, Food and Rural Affairs (MAFRA) – Policy announcements and funding details.
- World Organisation for Animal Health (OIE) – Global trends in animal disease and vaccine standards.
The next major checkpoint for South Korea’s vaccine program is the APQA’s annual biosecurity summit in October 2024, where preliminary results from the workshop’s Phase 1 prototypes are expected to be unveiled. Farmers and industry stakeholders are encouraged to submit feedback via the APQA’s public consultation portal.
As South Korea races to close critical gaps in its veterinary vaccine arsenal, the success of this initiative could serve as a blueprint for other nations seeking to bolster their biosecurity defenses. With global animal disease threats evolving rapidly, the workshop’s outcomes may well determine whether the country remains a net importer of vaccines—or becomes a leader in the field.
Dr. Helena Fischer is a physician and health journalist with an MD from Charité – Universitätsmedizin Berlin. She specializes in public health and medical innovation, with a focus on infectious diseases and healthcare policy.
Share your thoughts on South Korea’s vaccine strategy or ask questions about animal disease preparedness in the comments below. For more updates on global health and medical innovation, subscribe to World Today Journal.